Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Parkinson's Disease

  Free Subscription


2 J Neurol Neurosurg Psychiatry
1 Lancet Neurol
6 Mov Disord
1 Neurobiol Dis
2 Neurochem Res
1 Neurol Genet
10 Neurology
1 Neurosci Lett
1 Proc Natl Acad Sci U S A
2 Science

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    J Neurol Neurosurg Psychiatry

  1. RIJKS N, Potters WV, Dilai J, De Bie RMA, et al
    Combining 7T T2 and 3T FGATIR: from physiological to anatomical identification of the subthalamic nucleus borders.
    J Neurol Neurosurg Psychiatry. 2022;93:1019-1020.

  2. WANG J, Chau SWH, Lam SP, Liu Y, et al
    Prevalence and correlates of REM sleep behaviour disorder in patients with major depressive disorder: a two-phase study.
    J Neurol Neurosurg Psychiatry. 2022;93:1010-1017.
    PubMed         Abstract available

    Lancet Neurol

    Parkinson's disease needs an urgent public health response.
    Lancet Neurol. 2022;21:759.

    Mov Disord

  4. SURFACE M, Balwani M, Waters C, Haimovich A, et al
    Reply to: "Could Blood Hexosylsphingosine Be a Marker for Parkinson's Disease Linked with GBA1 Mutations"?
    Mov Disord. 2022;37:1782.

  5. GLEASON AM, Tayebi N, Lopez GJ, Sidransky E, et al
    Reply to: "Overlapping Ranges in Levels Indicate That Hexosylsphingosine Is Not a Clinically Relevant Biomarker for GBA1-Associated Parkinson's Disease".
    Mov Disord. 2022;37:1781-1782.

  6. REYES CJ, Asano K, Todd PK, Klein C, et al
    Repeat-Associated Non-AUG Translation of AGAGGG Repeats that Cause X-Linked Dystonia-Parkinsonism.
    Mov Disord. 2022 Aug 16. doi: 10.1002/mds.29183.
    PubMed         Abstract available

  7. SAFARPOUR D, Brumbach BH, Arena M, Quinn J, et al
    Gastrointestinal Motility and Response to Levodopa in Parkinson's Disease: A Proof-of-Concept Study.
    Mov Disord. 2022 Aug 15. doi: 10.1002/mds.29176.
    PubMed         Abstract available

  8. LI C, Lin J, Gu X, Hou Y, et al
    Mutation Screening of TFG in alpha-Synucleinopathy and Amyotrophic Lateral Sclerosis.
    Mov Disord. 2022;37:1756-1761.
    PubMed         Abstract available

  9. PAZ RM, Stahl AM, Rela L, Murer MG, et al
    D1/D5 Inverse Agonists Restore Striatal Cholinergic Interneuron Physiology in Dyskinetic Mice.
    Mov Disord. 2022;37:1693-1706.
    PubMed         Abstract available

    Neurobiol Dis

  10. OUN A, Sabogal-Guaqueta AM, Galuh S, Alexander A, et al
    The multifaceted role of LRRK2 in Parkinson's disease: From human iPSC to organoids.
    Neurobiol Dis. 2022 Aug 10:105837. doi: 10.1016/j.nbd.2022.105837.
    PubMed         Abstract available

    Neurochem Res

  11. DE ALMEIDA EJR, Ibrahim HJ, Chitolina Schetinger MR, de Andrade CM, et al
    Modulation of Inflammatory Mediators and Microglial Activation Through Physical Exercise in Alzheimer's and Parkinson's Diseases.
    Neurochem Res. 2022 Aug 13. pii: 10.1007/s11064-022-03713.
    PubMed         Abstract available

  12. ZHANG W, Liu J, Chen Q, Ding W, et al
    Identification of ADP/ATP Translocase 1 as a Novel Glycoprotein and Its Association with Parkinson's Disease.
    Neurochem Res. 2022 Aug 13. pii: 10.1007/s11064-022-03688.
    PubMed         Abstract available

    Neurol Genet

  13. JENSEN-ROBERTS S, Myers TL, Auinger P, Cannon P, et al
    A Remote Longitudinal Observational Study of Individuals at Genetic Risk for Parkinson Disease: Baseline Results.
    Neurol Genet. 2022;8:e200008.
    PubMed         Abstract available


  14. GROVER S, Kumar Sreelatha AA, Pihlstrom L, Domenighetti C, et al
    Genome-wide Association and Meta-analysis of Age at Onset in Parkinson Disease: Evidence From the COURAGE-PD Consortium.
    Neurology. 2022;99:e698-e710.
    PubMed         Abstract available

  15. JANSSEN DAALEN JM, Schootemeijer S, Richard E, Darweesh SKL, et al
    Lifestyle Interventions for the Prevention of Parkinson Disease: A Recipe for Action.
    Neurology. 2022;99.
    PubMed         Abstract available

  16. NIOTIS K, West AB, Saunders-Pullman R
    Who to Enroll in Parkinson Disease Prevention Trials? The Case for Genetically At-Risk Cohorts.
    Neurology. 2022;99.
    PubMed         Abstract available

  17. BERG D, Crotty GF, Keavney JL, Schwarzschild MA, et al
    Path to Parkinson Disease Prevention: Conclusion and Outlook.
    Neurology. 2022;99.
    PubMed         Abstract available

    Neuroprotective Trials in REM Sleep Behavior Disorder: The Way Forward Becomes Clearer.
    Neurology. 2022;99.
    PubMed         Abstract available

  19. MACKLIN EA, Coffey CS, Brumm MC, Seibyl JP, et al
    Statistical Considerations in the Design of Clinical Trials Targeting Prodromal Parkinson Disease.
    Neurology. 2022;99.
    PubMed         Abstract available

  20. SEIBYL JP, Kuo P
    What Is the Role of Dopamine Transporter Imaging in Parkinson Prevention Clinical Trials?
    Neurology. 2022;99.

  21. MIRELMAN A, Siderowf A, Chahine L
    Outcome Assessment in Parkinson Disease Prevention Trials: Utility of Clinical and Digital Measures.
    Neurology. 2022;99.
    PubMed         Abstract available

  22. MOLSBERRY SA, Hughes KC, Schwarzschild MA, Ascherio A, et al
    Who to Enroll in Parkinson Disease Prevention Trials? The Case for Composite Prodromal Cohorts.
    Neurology. 2022;99.
    PubMed         Abstract available

  23. CROTTY GF, Schwarzschild MA
    What to Test in Parkinson Disease Prevention Trials? Repurposed, Low-Risk, and Gene-Targeted Drugs.
    Neurology. 2022;99.
    PubMed         Abstract available

    Neurosci Lett

  24. ZHENG JH, Sun WH, Ma JJ, Wang ZD, et al
    Structural and functional abnormalities in Parkinson's disease based on voxel-based morphometry and resting-state functional magnetic resonance imaging.
    Neurosci Lett. 2022;788:136835.
    PubMed         Abstract available

    Proc Natl Acad Sci U S A

  25. MURRAY KA, Hu CJ, Griner SL, Pan H, et al
    De novo designed protein inhibitors of amyloid aggregation and seeding.
    Proc Natl Acad Sci U S A. 2022;119:e2206240119.
    PubMed         Abstract available


  26. DIAZ-ORTIZ ME, Seo Y, Posavi M, Carceles Cordon M, et al
    GPNMB confers risk for Parkinson's disease through interaction with alpha-synuclein.
    Science. 2022;377:eabk0637.
    PubMed         Abstract available

  27. MOLLENHAUER B, von Arnim CAF
    Toward preventing Parkinson's disease.
    Science. 2022;377:818-819.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.